Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Bollack, Ariane
- dc.contributor.author Shekari, Mahnaz
- dc.contributor.author Gispert López, Juan Domingo
- dc.contributor.author AMYPAD Consortium
- dc.date.accessioned 2025-02-18T06:16:24Z
- dc.date.available 2025-02-18T06:16:24Z
- dc.date.issued 2024
- dc.description.abstract Introduction: To support clinical trial designs focused on early interventions, our study determined reliable early amyloid-β (Aβ) accumulation based on Centiloids (CL) in pre-dementia populations. Methods: A total of 1032 participants from the Amyloid Imaging to Prevent Alzheimer's Disease-Prognostic and Natural History Study (AMYPAD-PNHS) and Insight46 who underwent [18F]flutemetamol, [18F]florbetaben or [18F]florbetapir amyloid-PET were included. A normative strategy was used to define reliable accumulation by estimating the 95th percentile of longitudinal measurements in sub-populations (NPNHS = 101/750, NInsight46 = 35/382) expected to remain stable over time. The baseline CL threshold that optimally predicts future accumulation was investigated using precision-recall analyses. Accumulation rates were examined using linear mixed-effect models. Results: Reliable accumulation in the PNHS was estimated to occur at >3.0 CL/year. Baseline CL of 16 [12,19] best predicted future Aβ-accumulators. Rates of amyloid accumulation were tracer-independent, lower for APOE ε4 non-carriers, and for subjects with higher levels of education. Discussion: Our results support a 12-20 CL window for inclusion into early secondary prevention studies. Reliable accumulation definition warrants further investigations.
- dc.description.sponsorship The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The AMYPAD PNHS is registered at www.clinicaltrialsregister.eu with the EudraCT Number: 2018-002277-22. This work was supported by the Alzheimer's Disease Data Initiative (ADDI).
- dc.format.mimetype application/pdf
- dc.identifier.citation Bollack A, Collij LE, García DV, Shekari M, Altomare D, Payoux P, et al. Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study. Alzheimers Dement. 2024 May;20(5):3429-41. DOI: 10.1002/alz.13761
- dc.identifier.doi http://dx.doi.org/10.1002/alz.13761
- dc.identifier.issn 1552-5260
- dc.identifier.uri http://hdl.handle.net/10230/69621
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Alzheimers Dement. 2024 May;20(5):3429-41
- dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115952
- dc.rights © 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Alzheimer's
- dc.subject.keyword Centiloid
- dc.subject.keyword Amyloid
- dc.subject.keyword Longitudinal PET
- dc.subject.keyword Quantification
- dc.subject.keyword Reliable accumulation
- dc.title Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion